The massive dilution (36M shares + 49.3M warrants) relative to a clinical-stage biotech with no revenue will pressure the stock. Monitor for any near-term pipeline catalysts that could offset dilution concerns; the $3.50 warrant exercise price may act as a ceiling.
Price Chart
Executive Summary
Pyxis Oncology priced a public offering of 36M shares and 49.3M common warrants at $2.90/share, raising ~$110M in gross proceeds. The offering is highly dilutive to existing shareholders, with potential additional dilution if all warrants are exercised for up to ~$172.6M more. This capital raise signals near-term cash needs for a clinical-stage biotech with no approved products.
Key Financial Metrics
Key Facts
- Offering of 36,047,919 shares of common stock plus 1,883,121 pre-funded warrants and 49,310,352 common warrants at $2.90/share
- Expected gross proceeds of approximately $110 million
- If all warrants exercised, additional gross proceeds of approximately $172.6 million
- Common warrant exercise price is $3.50 per share
- Pre-funded warrant price is $2.899 per share
Financial Impact
~$110M raised via highly dilutive offering; potential total dilution of up to ~87M shares (including warrants) vs. pre-offering share count of ~[not stated]
Risk Factors
- Extreme dilution to existing shareholders from share issuance and potential warrant exercise
- Clinical-stage company with no approved products — capital raise signals cash burn and potential need for further financing
- Warrant overhang may cap upside at $3.50 exercise price
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3371511 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $1.66 | awaiting T+5 | — | $1.84 (+10.84%) |
Oct 21, 2026 6d ago | DEF 14A | $1.71 | awaiting T+5 | — | $1.84 (−7.60%) |
Oct 9, 2026 18d ago | SC 13G/A | $2.03 $1.68 | ▼ −17.24% | ▼ −15.27% | $1.84 (−9.36%) |
Oct 2, 2026 25d ago | SC 13G/A | $2.14 $2.03 | ▼ −5.14% | ▼ −6.30% | $1.84 (−14.02%) |
Oct 2, 2026 25d ago | Press Release | $2.14 $2.03 | ▲ +5.14% | ▲ +6.30% | $1.84 (+14.02%) |
Oct 1, 2026 26d ago | 8-K | $2.14 $2.03 | ▲ +5.14% | ▲ +6.30% | $1.84 (+14.02%) |
Oct 1, 2026 26d ago | 424B5 | $2.19 $1.99 | ▲ +9.13% | ▲ +10.43% | $1.84 (+15.98%) |
Sep 30, 2026 27d ago | Press Release | $2.33 $2.01 | ▲ +13.73% | ▲ +15.65% | $1.84 (+21.03%) |
Sep 9, 2026 6w ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $1.84 (−45.56%) |
Sep 8, 2026 7w ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $1.84 (−52.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers